Clinical trial
A Study of Retrovir and Epivir Alone or in Combination With 141W94 in…
NCT00002195 · Glaxo Wellcome, Industry · Completed
Key facts
| NCT number | NCT00002195 |
|---|---|
| Title | A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients |
| Official title | A Phase III Trial to Evaluate the Safety and Antiviral Efficacy of 141W94 in Combination With Retrovir and Epivir Compared to Retrovir and Epivir Alone in Patients With HIV Infection. |
| Lead sponsor | Glaxo Wellcome, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Amprenavir, Lamivudine, Zidovudine |
| Enrollment | 290 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: